Food and Drug Administration (FDA) Disclosure:

The statements in this forum have not been evaluated by the Food and Drug Administration and are generated by non-professional writers. Any products described are not intended to diagnose, treat, cure, or prevent any disease.

Website Disclosure:

This forum contains general information about diet, health and nutrition. The information is not advice and is not a substitute for advice from a healthcare professional.

Cannabinoids in the Treatment of Epilepsy

Discussion in 'Medical Marijuana Usage and Applications' started by jainaG, Oct 14, 2015.

  1. #1 jainaG, Oct 14, 2015
    http://www.nejm.org/doi/full/10.1056/NEJMra1407304Cannabinoids in the Treatment of Epilepsy
    Daniel Friedman, M.D., and Orrin Devinsky, M.D.
    N Engl J Med 2015; 373:1048-1058September 10, 2015DOI: 10.1056/NEJMra1407304


    Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
    Dr.Devinsky reports receiving grant support from GW Pharmaceuticals and
    Novartis and serving on the scientific advisory board of MiaMed; and Dr.
    Friedman, receiving fees for serving on an advisory board for Marinus
    Pharmaceuticals and consulting fees from Eisai, Marinus Pharmaceuticals,
    SK Biopharmaceuticals, Upsher-Smith Laboratories, and Pfizer, all of
    which were paid to the Epilepsy Study Consortium. No other potential
    conflict of interest relevant to this article was reported.

    Source Information
    From the Department of Neurology, New York University Langone School of Medicine, New York.
    Address reprint requests to Dr. Friedman at the Department of Neurology, NYU
    Langone School of Medicine, 223 E. 34th St., New York, NY 10016, or at daniel.friedman@nyumc.org.


     

Share This Page